



RESULTS IN 3 TO 5 HOURS, NO BLOOD CULTURE REQUIRED

T2BACTERIA™ PANEL

RAPIDLY DETECT AND IDENTIFY BACTERIA SPECIES NO BLOOD CULTURE REQUIRED

RESULTS DIRECT FROM BLOOD DRAW

Rapid detection and identification of sepsis-causing pathogens are critical for optimizing antimicrobial therapy to improve patient survival and substantially reduce healthcare costs. T2 Magnetic Resonance (T2MR®) is the ONLY technology that may enable 95% of patients with bloodstream infections to receive targeted therapy within hours – when treatment has the biggest impact on patient outcomes.

ACTIONABLE IDENTIFICATION OF CRITICAL INFECTIONS

Currently in FDA-clinical trials, the T2Bacteria Panel identifies six of the most deadly and prevalent bacteria species that are often not covered by empiric therapy. As with the FDA-cleared and CE-marked T2Candida® Panel, species-specific results direct-from-whole-blood are available within hours of patient presentation.

PROVEN TECHNOLOGY, QUANTIFIABLE IMPACT

Today, implementation of the T2Candida Panel in over 140 hospitals globally has shortened length of stay, reduced antimicrobial consumption, and identified patients missed by blood culture.

The T2Bacteria Panel runs on the same T2Dx® Instrument as the T2Candida Panel and is designed to be used on patients presenting in the Emergency Department or symptomatic inpatients. Independent studies have proven that rapid detection and treatment can reduce patient mortality by 50% or more while reducing hospital and ICU length of stay by 3 to 7 days.

T2BACTERIA COVERAGE

Gram Negative:

Escherichia coli
Klebsiella pneumoniae
Pseudomonas aeruginosa
Acinetobacter baumannii

Gram Positive:


Staphylococcus aureus
Enterococcus faecium

PATIENT SELECTION CRITERIA

T2Bacteria patient testing should be on high-risk inpatients including all symptomatic patients e.g.

- ICU, oncology or transplant wards
- Patients with a CVC/line
- Includes Emergency Department (ED) patients
- Typically ~40% of all symptomatic patients

SIMPLE-TO-USE T2MR PLATFORM



EMPOWER HEALTHCARE TEAMS TO EFFECTIVELY TREAT UP TO 95% OF SEPTIC PATIENTS WITHIN HOURS OF PRESENTATION

TIMELY & ACCURATE RESULTS SUPPORT CLINICAL ACTION

Initial empiric antimicrobial therapy effectively treats about 60% of all septic patients.³ By focusing on those pathogens that often do not respond to initial empiric therapy, T2Bacteria and T2Candida results enable the administration of effective therapy within hours of patient presentation and long before blood culture-based results are available.

T2Bacteria and T2Candida results plus empiric therapy empower healthcare teams to effectively treat up to 95% of septic patients within hours of patient presentation.

IMPACT OF TIMELY, EFFECTIVE SEPSIS TREATMENT

- Decreased mortality rates
- Shortened length of stay
 - 3 to 7 ICU days saved
 - 1 to 7 hospital days saved
- Reduced use of antimicrobial drugs
- Reduced healthcare spending
 - Savings of ~\$25,000 per positive patient (US data)
- Improved healthcare quality metrics

1. Tsalik EL et al. Multiplex PCR to diagnose bloodstream infections in patients admitted from the emergency department with sepsis. *J Clin Microbiol.* 2010 Jan;48(1):26-33.
2. Lazzaro F et al. Prevalence and drug susceptibility of pathogens causing bloodstream infections in northern Italy: a two-year study in 16 hospitals. *Eur J Clin Microbiol Infect Dis.* 2002 Dec;21(12):849-55.
3. Buehler SS et al. Effectiveness of Practices To Increase Timeliness of Providing Targeted Therapy for Inpatients with Bloodstream Infections: a Laboratory Medicine Best Practices Systematic Review and Meta-analysis. *Clin Microbiol Rev.* 2016 Jan;29(1):59-103.
T2 Biosystems®, T2MR®, T2Candida®, T2Bacteria®, T2Dx®, and the T2Biosystems, Inc. logo are trademarks of registered trademarks of T2 Biosystems, Inc. All software and documentation is subject to T2 Biosystems, Inc. copyrights. ©2017 T2 Biosystems. All rights reserved. t2_497_R1 04/17

To learn more about how T2MR technology can impact the lives of your patients while potentially reducing your healthcare costs, visit www.t2biosystems.com

